Help Shape the Future of Denosumab Treatment
As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.
Take the survey now and make your voice heard
September 16th 2025
EASD 2025: The risk of developing the 4 primary subtypes of T2D was increased by as much as 3-fold and was not dependent on duration of smoking behavior.